Device Trial Radar · NCT01539239
Safety & Effectiveness Study of the Hydrus Microstent for Lowering IOP in Glaucoma Patients Undergoing Cataract Surgery (HORIZON)
Last checked: Nov 19, 2026Latest source record: Mar 12, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,143
Actual
Start
Jan 2012
Primary completion
Jun 2017
Study completion Jun 2020
Sponsor
- Lead sponsor
- Ivantis, Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Feb 27, 2012
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 45 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This clinical trial is a prospective, randomized, controlled, multicenter, study. After informed consent is obtained, patients will be evaluated for eligibility based on glaucoma severity, eye health, and visual acuity. Following successful screening, use of all topical glaucoma medications will be stopped for a period of "washout" to establish a qualifying medication-free intraocular pressure (IOP) value. Clinical follow up will be scheduled over the course of the 24 month study, and examinations will be repeated to monitor eye health. At the 1 and 2 year follow up, those patients on ocular hypotensive medications will be instructed to washout, and then have the diurnal (IOP taken in the morning, mid-day, and afternoon in the same day) IOP evaluation. Annual follow up will occur up to 5 years. The primary effectiveness endpoint is a decrease in diurnal IOP from baseline compared to the 24 months diurnal IOP following medication washout.
Conditions
- Primary Open Angle Glaucoma
Interventions
Hydrus Aqueous ImplantDevice
The Hydrus Aqueous Implant is a crescent-shaped nitinol device intended to be a permanent implant placed through the trabecular meshwork into Schlemm's Canal, immediately following placement of a monofocal IOL.
Cataract surgeryProcedure
A monofocal intraocular lens (IOL) placed during the cataract surgery.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Reduction in Mean Diurnal IOP From Baseline at 24 Months Following Medication Washout.Time frame: Baseline and 24 months
Locations
38 sites in 9 countries. Site status is shown where the registry gives one.
Site not named
Phoenix, Arizona
Site not named
Tucson, Arizona
Site not named
Fayetteville, Arkansas
35 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.